Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

Treatment changes of patients at the time of failure are shown in table 4. Fewer patients prescribed initial subcutaneous MTX changed the route of administration, increased the dose of MTX after 3 ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's ...